Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
prolonging spray.
Popular Articles

An Official End To WorkChoices - ANF Celebrates
The Australian Nursing Federation joined other unions in celebrating the end of WorkChoices.
generic viagra
H1N1: What You Should Know
As a Dallas-based physician, there has been a recent flurry of panic about the H1N1 (swine influenza). School districts closed down. Intramural sports statewide were cancelled. Some even suggested closing the border with Mexico, where approximately three quarters of a million people routinely cross back and forth every day. The panic certainly was fueled by the media reports. Likewise, the media can serve to educate the public about health issues.
Zubni implantati
News of the day
FDA Approves SAMSCA(TM) (tolvaptan), The First And Only Oral Vasopressin Antagonist To Treat Patients With Clinically Significant Hypervolemic
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) announced that the U.S. Food and Drug Administration (FDA) has approved SAMSCA(TM) (tolvaptan) as the only oral selective vasopressin antagonist for the treatment of patients with clinically significant hypervolemic and euvolemic hyponatremia (serum sodium less than 125 mEq/L, or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction) including patients with heart failure, cirrhosis, and the syndrome of inappropriate anti-diuretic hormone (SIADH). Patients requiring urgent treatment to raise serum sodium to prevent or to treat serious neurological deficits should not be treated with SAMSCA. Additionally, it has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients. SAMSCA, an oral vasopressin V2-receptor antagonist, will be commercialized in the United States by Otsuka America Pharmaceutical, Inc. (OAPI).
Public Health

10 Million H1N1 Vaccines Ordered By Australia

Reports are coming in that the government of Australia has placed an order for 10 million vaccines against the novel H1N1 swine flu virus, following a press briefing from Health Minister Nicola Roxon in Canberra earlier today, Thursday. According to a report from Reuters, Roxon said the Australian government will also be ordering 1.6 million courses of the antiviral drug Relenza, bringing the national stockpile of antivirals to nearly 12 million courses. The swine flu vaccine order has been placed with pharmaceutical company CSL Ltd who are planning to start clinical trials in a few months. Vaccine producers worldwide have to wait for good "candidate" samples of the virus to be made in approved labs before they can start developing the vaccine. These are only just starting to come forward. It is not clear whether the order is for doses or courses. If it is for doses and experts conclude that two doses are needed for full immunity, then this order will only cover 25 per cent of Australia"s 20 million inhabitants. Roxon told reporters that the health authorities will be deciding who gets the vaccine and who does not. She said the government has also approved its first release of a controlled number of antivirals from the national stockpile to highly localized and targeted areas in the Victoria and Western Australia states to "enable aggressive containment of small clusters of the disease," reported Reuters. Earlier today, the Australian authorities reported they have officially confirmed 103 cases of H1N1 swine flu, up from 61 on Wednesday. Australia is also gearing up for the regular flu season, which starts about now, as the winter months approach. Most of the swine flu cases are believed to be in New South Wales and Victoria, the country"s two most populated states and which lie to the south east. Three of the cases were passengers travelling on the cruise liner Pacific Dawn which is now not going to complete its journey north to Queensland. As of 06:00 GMT yesterday, Wednesday 27 May, the World Health Organization (WHO) said that 48 countries have now officially reported 13,398 cases of H1N1 swine flu, including 95 deaths. Most of the deaths have been in Mexico, while most of the cases are in the US and Mexico. s: Reuters, WHO. Written by: Catharine Paddock, PhD Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009